Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol

NEXT STORY
Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference
PREV STORY
NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Emerald Bioscience’s NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol

NEXT STORY
Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference
PREV STORY
NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

author_avatar
NASDAQ Market News

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

author_avatar
NASDAQ Market News

Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit

author_avatar
NASDAQ Market News